1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Cardiovascular Risk Factors-Pipeline Insights, 2014

SUMMARY
DelveInsight’s,“ Cardiovascular Risk Factors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Cardiovascular Risk Factors. This report provides information on the therapeutic development based on the Cardiovascular Risk Factors dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Cardiovascular Risk Factors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Cardiovascular Risk Factors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Cardiovascular Risk Factors and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Cardiovascular Risk Factors
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Cardiovascular Risk Factors pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

Cardiovascular Risk Factors-Pipeline Insights, 2014
Table of Contents
- Cardiovascular Risk Factors Overview
- Cardiovascular Risk Factors Pipeline Therapeutics
- Cardiovascular Risk Factors Therapeutics under Development by Companies
- Cardiovascular Risk Factors Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Cardiovascular Risk Factors Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Cardiovascular Risk Factors Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Cardiovascular Risk Factors Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Cardiovascular Risk Factors - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cardiovascular Risk Factors - Discontinued Products
- Cardiovascular Risk Factors - Dormant Products
- Companies Involved in Therapeutics Development for Cardiovascular Risk Factors
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Cardiovascular Risk Factors, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Cardiovascular Risk Factors Assessment by Monotherapy Products
- Cardiovascular Risk Factors Assessment by Combination Products
- Cardiovascular Risk Factors Assessment by Route of Administration
- Cardiovascular Risk Factors Assessment by Stage and Route of Administration
- Cardiovascular Risk Factors Assessment by Molecule Type
- Cardiovascular Risk Factors Assessment by Stage and Molecule Type
- Cardiovascular Risk Factors Therapeutics - Discontinued Products
- Cardiovascular Risk Factors Therapeutics - Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Cardiovascular Risk Factors, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Cardiovascular Risk Factors Assessment by Monotherapy Products
- Cardiovascular Risk Factors Assessment by Combination Products
- Cardiovascular Risk Factors Assessment by Route of Administration
- Cardiovascular Risk Factors Assessment by Stage and Route of Administration
- Cardiovascular Risk Factors Assessment by Molecule Type
- Cardiovascular Risk Factors Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Cardiovascular Surgical Devices: Technologies and Global Markets

Cardiovascular Surgical Devices: Technologies and Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Learn about the trends and developments affecting each type of cardiovascular surgical technology - Analyze trends and opportunities in major regions: North America, Europe, Asia ...

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021). Over the ...

Refurbished Medical Equipment Market: By Type (Medical Imaging, Operating Room & Surgical, Patient Monitors, Cardiovascular & Cardiology, Defibrillators, Neurology, Others) & By Region-Forecast (2016-2021)

Refurbished Medical Equipment Market: By Type (Medical Imaging, Operating Room & Surgical, Patient Monitors, Cardiovascular & Cardiology, Defibrillators, Neurology, Others) & By Region-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Refurbished medical equipment market is being primarily driven by factors like development of e-commerce platform enhancing the ease of purchase of refurbished medical equipment, growing demand for refurbished ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.